The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.

Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.


If you have any questions you can fill in the form or mail us directly:


The Porto meeting of the TRAIN-HEART network was a major success

In Porto, 25 scientists and supervisors attended the 7th network meeting face-to-face between 16-18 February. Over 20 network members attended online. Beside two intense but inspiring days of research and progress presentations, a full-day of training was organised by Mirabilis Therapeutics on Intellectual Property Rights and Entrepreneurship. Overall, the meeting was a major success and we look forward to meeting each other once more later this year in Milan, Italy.